Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That quote is learningcurve’s.
DCVax-l long term five year survival is real in 13% of patients treated in the phase iii glioblastoma trial. Glioblastoma is exponentially more difficult to treat than B cell lymphoma. Car-T, and Car-T cells wipe out healthy B cells as well as cancerous ones to achieve their temporary effect.
In Glioblastoma, DCVax-l long term survival with poly-iclc appears to be significantly better. The safety and quality of life, and cost is far better for DCVax-l treated patients. Add Csf1r to that mix, and you may be near a cure.
You believe the science behind DCVax-l is respectable and demonstrates signals of efficacy, but you spend ten years here hoping to force its downfall. You won’t succeed, imo.
At the same time you try to argue the science, you intermittently claim you don’t know enough to comment on the science, and claim you are only here to complain about governance. Geesh.
1945
Somewhere on a battle field in the U.S. Army
General: Get all these soldiers inoculated against the flu.
learningcurve2020: No General, wait. The flu vaccine doesn’t work!!!
General: Why is that civilian?
learningcurve2000: It doesn’t cause enough side effects!!!
General: Where’s a doctor, this civilian is shell shocked!
Incorrect, instead, tumor stabilization can occur within eight weeks or less from treatment initiation in cases where responses are viable.
If the person doesn’t have an autoimmune disease, the body is programmed not to invent one, because there are no matching t-cells randomly generated and saved that will match any lysate offered self-antigens. Over a decade at this and you refuse to understand why it is safe.
You are thinking about Car-T cells, where engineers intentionally bypass/overide the safety features embedded in the immune system. They intentionally go after self as well as cancer mutations.
DCVax-l, on the other hand, does not override the immune system’s safety features. Instead, it works with the immune system.
Thanks bas2020. That’s what I think as well. In addition, Alzheimer’s progression is very subjective between those degrees, and like pain medicines, Alzheimer’s treatment benefits are very difficult to tease out.
I hope you are also correct that blarcamesine will be superior.
I assume when you keep saying “you,” you are referring to “Elsie.”
Violent deaths five days apart after not guilty verdicts earlier in the year. 😬
Wrong. Instead, the immune system is trained to go after foreign bodies, bacteria, viruses and mutations, but it is specifically and uniquely trained from birth to avoid going after self. That’s why diseases like lupus and RA are anomalies, and even then, the immune system restrains itself from going full steam against self.
DCVax-l is not trained to go after self, because it can’t be trained to go after self. There are no matching t-cells to accommodate your fantasies. That’s why its side effects are mostly limited to inflammation (fever,swelling at injection site,etc), the kind your body develops when it is fighting a disease.
learningcurve2020:
Yesterday
learningcurve2020:
December 2023
Don’t share it if you are going to talk about inside info. I assume you are speaking in more general terms about looking for other examples.
Do you have historical examples of such splits in M&A, and how did those work out?
Ok. Thanks.
Thanks, thought I saw a small gap between 3:45 and 3:50 (just below .36 cents) It would be great if you are right and there was no gap.
I’ll find your quote later. Here is one of ex’s from October 2023.
I’d buy that small innovative company before some behemoth bp acquires it without so much as a wave of their hand. (To answer your question below)
It gapped up. Correct? So, whatever gap god controls these things, it’s supposed to go back down in hours, days, weeks or months to fill that gap. Correct? Unless there is a gap up and never look back, which this stock has not seen — yet. Last year at this time, we made a run. This year, there is a speculative reason to run (not just that summer is essentially over in a week).
Even learning curve and Ex admit the science is strong for this company.
The Direct patents are strong and relatively new.
The combination patent is strong and relatively new.
The flaskworks patents are new and very strong, and create a higher barrier to entry.
The new company we acquired seems like its IP will form a wider barrier to entry.
Our patents pending, particularly for hyperactive dendritic cells is very new.
The various exclusive use protections can go into effect upon any forthcoming approval.
The potential cancer indications are limitless.
If I were a medium size BP like Merck, I’d start to worry huge pharma like Lilly, NovoNordisk (Dr. Bosch also in Denmark) or even Johnson could buy NWBO without blinking, and fully enter the immunotherapy cancer field at the same time Keytruda is about to go off patent.
Just an early weekend musing. Or we go back down and fill the gap. Or something else.
The law. You can’t advertise therapeutics that do not have a marketing license (aka license to sell)
I’m wondering if the accounting shows Les’s strange trust transfers and “annuity” payment add up to no sales thereafter. I’m simply not sophisticated enough in accounting to know what he did with those 12 million options transferred back to him from his trust, but I assume he made no conversions or sales. If he did, especially if he did just before May 10, 2022, I’d be very very confused. However, I’m assuming he still holds those options. So I’m assuming it was just Les being quirky.
Again, my thinking is they are now wanting to time the commercial Eden units’ arrival to coincide with maa approval* so that the commercial Eden units are tested in parallel with the artisan commercial production method, as opposed to testing them in parallel with the compassionate artisan production method.
That’s precisely what the timing at this point seems to indicate.
(* assuming approval)
It’s against the law to carry out phase human medical trials without publicly registering them. End of story.
No secret human clinical therapy trials. It’s not allowed. It’s ridiculous to argue with you further on this, but please, don’t let me stop you from posting.
In 2004, the European Union mandated that all clinical trials conducted in Europe must be registered in a publicly accessible database. This requirement was established by the European Clinical Trials Directive (2001/20/EC), which aimed to enhance transparency and public access to information about clinical trials for drugs and biologics. The EU Clinical Trials Register was later launched to provide information on these trials.
Trials have to be listed on clinical trials.gov (or some other government’s public regulatory system in the unlikely event NWBO does not start with clinical trials.gov.
Lilly’s so rich, it could acquire NWBO and not even notice a scratch in its finances.
See post 715237.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174973683
(Personally, I assume the unit, given a little more time to maa approval, underwent a Steve Jobs’ or Howard Hugh’s like makeover, increasing sleekness, condensing footprint, and simply more aesthetic. Nothing “cell facing,” imo.
That was more of a Scotty quip by you.
That said, it looks like Eden units’ arrival will be timed almost precisely to commercial approval* (aka marketing license) in order to test Eden alongside artisan commercial production.
I can only assume that seems to be the plan.
* (Assuming approval in near term)
For any of you that speak to DI, please ask if LP is going to surprise us with any more preconditions to Eden deliveries — the latest having been size footprint. That was an annoying delay development which should have been done earlier, imo. Hopefully it’s complete.
Who here thinks NWBO could let cdf fund DCVax-l at cost until Eden? Once Eden up, NICE/MHRA fund approximately same price or somewhat more, but huge profit margin.
Anyone think this novel approach might work?
Remember, it is likely the Eden patients are experimental until equivalency approved.
It just seems like we have to account for LP’s ASM expressed NICE filing lag time. I think the above might explain it.
I don’t think you can draw a news or no news conclusion out of the spike in dilution. It means something, but it typically means keeping the lights on. Still, because NWBO is not in control the timeline for the next major expected events, you can’t draw much from dilution. For example, they could dilute, then find out the very next day a court decision and a regulatory decision were made.
They run the compassionate production through Sawston, and Sawston is licensed for clinical and commercial production of cell products, and the product process they used to obtain these licenses was for DCVax-l.
You are right about not knowing much about the MHRA process. The FDA doesn’t even have compassionate use programs.
In the U.S. the phase III trial did utilize Cognate’s manufacturing. So there’s that.
They have already released interim results.
Navid’s behavior is a nothing burger.